Inhibiting HER2 shedding with matrix metalloprotease antagonists

Details for Australian Patent Application No. 2006213659 (hide)

Owner Genentech, Inc.

Inventors Sliwkowski, Mark X.; Schwall, Ralph H.; Carey, Kendall D.

Agent Griffith Hack

Pub. Number AU-A-2006213659

PCT Pub. Number WO2006/086730

Priority 60/651,348 09.02.05 US

Filing date 9 February 2006

Wipo publication date 17 August 2006

International Classifications

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 35/00 (2006.01) Antineoplastic agents

C12N 9/64 (2006.01) Enzymes, e.g. ligases (6.) - derived from animal tissue, e.g. rennin

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

16 August 2007 PCT application entered the National Phase

  PCT publication WO2006/086730 Priority application(s): WO2006/086730

18 March 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006213662-Process for preparing maytansinoid antibody conjugates

2006213657-Techniques to reduce false alarms, invalid security deactivation, and internal theft